SAR444245, a non‐alpha IL2, rescues chronic antigen and CAR‐driven T‐cell dysfunction

Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), M. R. Green(The University of Texas MD Anderson Cancer Center), Roberto Carrió(Sanofi (United States)), Margot Cucchetti(Sanofi (France)), Julie-Ann Gavigan, Virna Cortez‐Retamozo(Vrije Universiteit Brussel), Patrick K. Reville(The University of Texas MD Anderson Cancer Center), James Cao(Sanofi (Mexico)), Ingrid Sassoon(Sanofi (France)), Qian Yu(J. Craig Venter Institute), Nathan Pate(Sanofi (Mexico)), Chunhua Shi(AVEO Oncology (United States)), Dinesh S. Bangari(Sanofi (United States)), Donald R. Shaffer(The University of Texas MD Anderson Cancer Center), Emilio Rojas(Universidad Nacional Autónoma de México), Elamaran Meibalan(Harvard University), April Choi(AVEO Oncology (United States)), Mansi Agarwal(Washington University in St. Louis), Katie Malley(Sanofi (Mexico)), Giovanni Abbadessa(Morristown Medical Center), C. Okwuchi(The University of Texas MD Anderson Cancer Center), Ruikang K. Wang(Jilin University), Xiangming Li(The University of Texas MD Anderson Cancer Center), Sukhvinder Sidhu(The University of Sydney), C. Le(The University of Texas MD Anderson Cancer Center), Baoli Liu(Beijing Hospital of Traditional Chinese Medicine), Jun Jiao(Nankai University), X. Ying(AVEO Oncology (United States)), T. Byers(University of Colorado Denver), L. Powers(AVEO Oncology (United States)), Kelly Balko(Sanofi (France)), J. Henderson(The University of Texas MD Anderson Cancer Center)
Hematological Oncology
June 1, 2023
Cited by 0


Related Papers